Cargando…

CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem

OBJECTIVE: To verify whether CYP polymorphisms are associated with amyloid-β (Aβ) pathology across the spectrum of clinical Alzheimer disease using in vivo and postmortem data from 2 independent cohorts. METHODS: A candidate-gene approach tested the association between 5 genes (28 single nucleotide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benedet, Andréa L., Yu, Lei, Labbe, Aurélie, Mathotaarachchi, Sulantha, Pascoal, Tharick A., Shin, Monica, Kang, Min-Su, Gauthier, Serge, Rouleau, Guy A., Poirier, Judes, Bennett, David A., Rosa-Neto, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820598/ https://www.ncbi.nlm.nih.gov/pubmed/29473050 http://dx.doi.org/10.1212/NXG.0000000000000216

Ejemplares similares

Epistasis analysis links immune cascades and cerebral amyloidosis
por: Benedet, Andréa L., et al.
Publicado: (2015)

VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis
por: Mathotaarachchi, Sulantha, et al.
Publicado: (2016)

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Characterizing biomarker features of cognitively normal individuals with ventriculomegaly
por: Li, Xiaofeng, et al.
Publicado: (2017)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease
por: Ng, Kok Pin, et al.
Publicado: (2017)

Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease
por: Ng, Kok Pin, et al.
Publicado: (2021)

APOEε4 potentiates the relationship between amyloid-β and tau pathologies
por: Therriault, Joseph, et al.
Publicado: (2020)

Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Imaging Alzheimer's disease pathophysiology with PET
por: Schilling, Lucas Porcello, et al.
Publicado: (2016)

Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia
por: Savard, Melissa, et al.
Publicado: (2022)

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia
por: Therriault, Joseph, et al.
Publicado: (2018)

Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy
por: Ng, Kok Pin, et al.
Publicado: (2019)

Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment
por: Pascoal, Tharick A., et al.
Publicado: (2020)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
por: Wang, Yi-Ting T, et al.
Publicado: (2021)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
por: Pascoal, T A, et al.
Publicado: (2017)

In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
por: Kang, Min Su, et al.
Publicado: (2020)

Dynamic Amyloid and Metabolic Signatures of Delayed Recall Performance within the Clinical Spectrum of Alzheimer’s Disease
por: Tedeschi Dauar, Marina, et al.
Publicado: (2023)

Aβ-induced vulnerability propagates via the brain’s default mode network
por: Pascoal, Tharick A., et al.
Publicado: (2019)

Targeting Alzheimer’s Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment
por: Gauthier, Serge, et al.
Publicado: (2018)

Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
por: Ng, Kok Pin, et al.
Publicado: (2017)

Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images
por: Sharafi, Sayed Mehran, et al.
Publicado: (2019)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals
por: Lussier, Firoza Z., et al.
Publicado: (2020)

Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease
por: Schoemaker, Dorothee, et al.
Publicado: (2015)

Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease
por: Zhang, Hua, et al.
Publicado: (2018)

Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease
por: Zhang, Hua, et al.
Publicado: (2018)

Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic
por: Kang, Min Su, et al.
Publicado: (2021)

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Constrained instruments and their application to Mendelian randomization with pleiotropy
por: Jiang, Lai, et al.
Publicado: (2019)

Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer’s disease
por: Fernández Arias, Jaime, et al.
Publicado: (2023)

Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
por: Pascoal, Tharick A., et al.
Publicado: (2023)

Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment
por: Therriault, Joseph, et al.
Publicado: (2021)

Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease
por: Therriault, Joseph, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c61hito0ibmq94ev9sm1qrdhpa